Does Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Pay Compare Well With Peers?HomeMailNewsFinanceSportsEntertainmentSearchMobileMoreYahooSearchNo matching results for ''Tip: Try a valid symbol or a specific company name for relevant resultsSign inMailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Does Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Pay Compare Well With Peers?Simply Wall StSimply Wall St.January 7, 2020ReblogShareTweetShareView photosNadav Kidron became the CEO of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) in 2006. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at a snap shot of the business growth. And finally - as a second measure of performance - we will look at the returns shareholders have received over the last few years. This method should give us information to assess how appropriately the company pays the CEO. See our latest analysis for Oramed Pharmaceuticals How Does Nadav Kidron's Compensation Compare With Similar Sized Companies?Our data indicates that Oramed Pharmaceuticals Inc. is worth US$81m, and total annual CEO compensation was reported as US$1.6m for the year to August 2019. That's just a smallish increase of 0.07% on last year. While we always look at total compensation first, we note that the salary component is less, at US$419k. Importantly, there may be performance hurdles relating to the non-salary component of the total compensation. We looked at a group of companies with market capitalizations under US$200m, and the median CEO total compensation was US$524k.It would therefore appear that Oramed Pharmaceuticals Inc. pays Nadav Kidron more than the median CEO remuneration at companies of a similar size, in the same market. However, this fact alone doesn't mean the remuneration is too high. We can get a better idea of how generous the pay is by looking at the performance of the underlying business.You can see, below, how CEO compensation at Oramed Pharmaceuticals has changed over time.NasdaqCM:ORMP CEO Compensation, January 7th 2020MoreIs Oramed Pharmaceuticals Inc. Growing?Over the last three years, Oramed Pharmaceuticals Inc. has not seen its earnings per share change much, though there is a positive trend. It achieved revenue growth of 10% over the last year.I think the revenue growth is good. And the improvement in earnings per share is modest but respectable. So while we'd stop just short of calling this a top performer, but we think it is well worth watching. It could be important to check this free visual depiction of what analysts expect for the future.Has Oramed Pharmaceuticals Inc. Been A Good Investment?With a three year total loss of 24%, Oramed Pharmaceuticals Inc. would certainly have some dissatisfied shareholders. This suggests it would be unwise for the company to pay the CEO too generously.In Summary...We compared the total CEO remuneration paid by Oramed Pharmaceuticals Inc., and compared it to remuneration at a group of similar sized companies. As discussed above, we discovered that the company pays more than the median of that group.While we have not been overly impressed by the business performance, the shareholder returns, over three years, have been disappointing. Shareholders may wish to consider further research. Although we don't think the CEO pay is too high, it is probably more on the generous side of things. So you may want to check if insiders are buying Oramed Pharmaceuticals shares with their own money (free access).Important note: Oramed Pharmaceuticals may not be the best stock to buy. You might find something better in this list of interesting companies with high ROE and low debt. If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoPublic Storage only bidder left for National Storage with $1.25 billion bidReuters'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoBaidu says first-quarter revenue may tumble as coronavirus takes toll on business, advertisingReutersDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceSomething 'dangerous' is happening beneath the surface of the market selloffYahoo FinanceBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance